Gefjon Pharma has developed a groundbreaking platform technology based on our unique hyper vesiculating outer membrane vesicle (OMV) technology. This combined with our unique extraction method enable high-yield cost-effective production of bio-industrials and therapeutics. Our first product is a revolutionary broad-protective bacterial E. coli vaccine targeting poultry production. We have PoC for both the vaccine and an aerosol application method. With E. coli being the single most important cause of mortality and infections in poultry, we will significantly reduce global consumption of antimicrobials, thereby minimizing the development of antimicrobial resistance (AMR), improve animal welfare, and reduce CO2 emissions and food waste, while increasing customer profits. With our excellent customer relations and a strong demand for new vaccines, market entry barriers are low, and the potential is massive.
Vision: Saving lives through our platform technology, making cost-effective therapeutics available for everyone & everywhere
Mission: We want to disrupt the poultry E. coli vaccine market being market leaders within the next 5-10 years